APX and Revelle Enter Strategic Partnership
The partnership between APX and Revelle aims to help aesthetic practices accelerate growth and productivity.
The partnership between APX and Revelle aims to help aesthetic practices accelerate growth and productivity.
Available in the EU, UK, and Switzerland, the device is designed for in-office preparation of autologous PRP and Fluid-PRF.
A randomized controlled study of Sofwave’s FDA-cleared Pure Impact VIP platform found functional gains, with most improvements sustained four weeks after treatment.